It involves weekly semaglutide injections that have shown impressive resultsan average weight reduction of 14.9% in clinical trials
Semaglutide is the active ingredient in three medications: Ozempic, Wegovy, and Rybelsus
doi:10.1016/j.mad.2003.11.005 Huff T, Mller CS, Otto AM, Netzker R, Hannappel E
Reducing the dose may help if lightheadedness is persistent
Remember your resistance: Resistance training, that is
TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension